Point-of-care heart failure platform: where are we now and where are we going to?

被引:2
|
作者
Berezin, Alexander E. [1 ]
Berezin, Alexander A. [2 ]
机构
[1] Zaporozhye State Med Univ, Internal Med Dept, 26 Mayakovsky Av, Zaporozhe, Ukraine
[2] Zaporozhye Med Acad Postgrad Educ, Internal Med Dept, Zaporozhe, Ukraine
关键词
Heart failure; point-of-care therapy; biomarker-guided therapy; translational therapy; guideline-directed medical therapy; REDUCED EJECTION FRACTION; GROWTH-DIFFERENTIATION FACTOR-15; NATRIURETIC PEPTIDE ASSAY; CARDIAC TROPONIN ASSAYS; HIGH-SENSITIVITY; NT-PROBNP; MULTICENTER EVALUATION; COST-EFFECTIVENESS; GUIDED THERAPY; PERFORMANCE-CHARACTERISTICS;
D O I
10.1080/14779072.2022.2080657
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Heart failure (HF) remains a leading cause of cardiovascular (CV) mortality in patients with CV disease. The point-of-care (POC) HF platform seems to be an ideal noninvasive workflow-adapted system for personally adjusted management of patients with HF. Areas covered: In the present manuscript, we reviewed the literature covering some relevant studies regarding the role of point-of care heart failure platform in the risk stratification, earlier diagnosis and prognostically beneficial treatment of patients with different phenotypes of HF. Expert opinion: POC HF platform including personal consultation, optimization of the comorbidity treatment, step-by-step HF diagnostic algorithm, single biomarker measurements, has also partially been provided in the current guidelines. Although there are several obstacles to implement POC in routine practice, such as education level, aging, affordability of health care, even partial implementation of POC can also improve clinical outcomes. POC seems to be an evolving model, more research studies are required to clearly see whether it helps to make better decisions with diagnosis and care of HF, as well helps to achieve better clinical outcomes. In summary, the POC HF platform is considered to be a more effective tool than conventional algorithm of HF management.
引用
收藏
页码:419 / 429
页数:11
相关论文
共 50 条
  • [1] Prognostic scores in advanced heart failure: where are we now and where are we going?
    Nessler, Jadwiga
    Rostoff, Pawel
    [J]. POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2017, 127 (04): : 235 - 237
  • [2] Delirium care: where are we now and where are we going?
    Maclullich, Alasdair
    [J]. AUSTRALASIAN JOURNAL ON AGEING, 2015, 34 : 11 - 11
  • [3] WHERE ARE WE NOW AND WHERE ARE WE GOING
    KARLAN, BY
    [J]. GYNECOLOGIC ONCOLOGY, 1995, 59 (03) : 315 - 317
  • [4] Where Are We Now and Where Are We Going?
    Sempokuya, Tomoki
    McDonald, Nicholas
    [J]. ACG CASE REPORTS JOURNAL, 2023, 10 (05)
  • [5] Chlamydia point-of-care testing: where are we now?
    Jain, Anu
    Ison, Catherine A.
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2013, 89 (02) : 88 - 89
  • [6] Point-of-care device communication: Where are we now?
    Reynolds, M
    Ruiz, R
    Woolman, P
    [J]. MEDICON 2001: PROCEEDINGS OF THE INTERNATIONAL FEDERATION FOR MEDICAL & BIOLOGICAL ENGINEERING, PTS 1 AND 2, 2001, : 209 - 211
  • [7] The total artificial heart: where have we been, where are we now, where are we going?
    Arabia, Francisco A. A.
    Murray, Catherine Friederich
    [J]. INDIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 39 (SUPPL 1) : 198 - 205
  • [8] The total artificial heart: where have we been, where are we now, where are we going?
    Francisco A. Arabía
    Catherine Friederich Murray
    [J]. Indian Journal of Thoracic and Cardiovascular Surgery, 2023, 39 : 198 - 205
  • [9] ALUMINUM - WHERE ARE WE NOW, WHERE ARE WE GOING
    不详
    [J]. METALLURGIA, 1981, 48 (07): : 298 - &
  • [10] Natriuretic peptides in heart failure: where we are, where we are going
    Palazzuoli, Alberto
    Antonelli, Giovanni
    Quatrini, Ilaria
    Nuti, Ranuccio
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2011, 6 (01) : 63 - 68